PROTHENA CORPORATION PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.56 USD | -3.43% |
|
-3.66% | -43.42% |
| Mar. 04 | Prothena Names David Ford as Chief People Officer | MT |
| Mar. 04 | Prothena Appoints David Ford to Newly Created Chief People Officer | CI |
Financials (USD)
| Sales 2024 * | 13.36M | Sales 2025 * | 118M | Capitalization | 1.1B |
|---|---|---|---|---|---|
| Net income 2024 * | -262M | Net income 2025 * | -220M | EV / Sales 2024 * | 36.1 x |
| Net cash position 2024 * | 623M | Net cash position 2025 * | 558M | EV / Sales 2025 * | 4.64 x |
| P/E ratio 2024 * |
-4.43
x | P/E ratio 2025 * |
-5.49
x | Employees | 173 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.56% |
More Fundamentals
* Assessed data
More news
Latest transcript on Prothena Corporation plc
More recommendations
More press releases
| 1 day | -3.43% | ||
| 1 week | -3.66% | ||
| Current month | -17.00% | ||
| 1 month | -19.06% | ||
| 3 months | -38.97% | ||
| 6 months | -51.35% | ||
| Current year | -43.42% |
1 week
20.42
21.79
1 month
20.4226.36
Current year
20.4241.55
1 year
20.4279.65
3 years
20.4279.75
5 years
6.7179.75
10 years
6.7179.75
| Managers | Title | Age | Since |
|---|---|---|---|
Gene Kinney
CEO | Chief Executive Officer | 55 | 12-11-30 |
Tran Nguyen
DFI | Director of Finance/CFO | 50 | 13-02-28 |
Wagner M. Zago
CTO | Chief Tech/Sci/R&D Officer | 51 | 11-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Richard Collier
BRD | Director/Board Member | 70 | 12-12-19 |
Gene Kinney
CEO | Chief Executive Officer | 55 | 12-11-30 |
Helen Kim
BRD | Director/Board Member | 61 | 22-07-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.85% | 16 M€ | -7.93% | ||
| 0.27% | 0 M€ | 0.00% | - | |
| 0.26% | 0 M€ | 0.00% | - | |
| 0.10% | 12 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-22 | 21.29 | +0.61% | 394,525 |
| 24-04-19 | 21.16 | +2.87% | 508,532 |
| 24-04-18 | 20.57 | -2.05% | 567,688 |
| 24-04-17 | 21 | -1.59% | 465,517 |
| 24-04-16 | 21.34 | -2.96% | 479,739 |
Delayed Quote Nasdaq, April 23, 2024 at 04:00 pm EDT
More quotes
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Companyâs pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimerâs disease, Parkinsonâs disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinsonâs disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimerâs disease.
Calendar
2024-05-06
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
21.29
USD
Average target price
66.09
USD
Spread / Average Target
+210.43%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -43.42% | 1.14B | |
| -0.49% | 103B | |
| +3.31% | 96.73B | |
| +1.66% | 21.31B | |
| -16.16% | 21.21B | |
| -6.82% | 18.79B | |
| -41.41% | 16.37B | |
| -22.87% | 13.68B | |
| +6.32% | 13.44B | |
| +21.46% | 10.98B |
- Stock Market
- Equities
- PRTA Stock
